NEW YORK, Aug. 17, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has joined the Critical Path Institute’s (“C-Path’s”) Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science. C-Path ( www.


Previous articleField Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results
Next articlePT258 – Manesh Girn – Psychedelics and the Brain: Neuroplasticity and Creativity